Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel

Reshma Mahtani

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel

Reshma Mahtani

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Breast
Volume	66
State	Published - Dec 1 2022

Cite this

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel. / Mahtani, Reshma.
In: Breast, Vol. 66, 01.12.2022.

Research output: Contribution to journal › Article › peer-review

@article{fe056e5c5f8e4e3d8ec0a65fb72cac7d,

title = "Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel",

author = "Reshma Mahtani",

note = "Breast (2022) 66:236-244",

year = "2022",

month = dec,

day = "1",

language = "American English",

volume = "66",

journal = "Breast",

}

TY - JOUR

T1 - Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel

AU - Mahtani, Reshma

N1 - Breast (2022) 66:236-244

PY - 2022/12/1

Y1 - 2022/12/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4578

M3 - Article

VL - 66

JO - Breast

JF - Breast

ER -

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel

Other files and links

Cite this